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Abstract
Objective To present a case of ventricular tachycardia
following naloxone administration and to review current
literature concerning ventricular tachycardia associated
with naloxone.
Methods We present a case and review the literature
concerning ventricular tachycardia (VT) as a complication
of naloxone administration.
Results In our patient, a 44-year old male intoxicated
multi-drug user, VT presented on the electrocardiogram
shortly after naloxone (twice 0.4 mg intra-osseous)
administration for suspected methadone overdose. After
initial medical treatment he was treated with electro car-
dioversion because of hemodynamic instability. Our
patient was subsequently stabilized and admitted to our
intensive care unit (ICU). Eight comparable cases con-
cerning VT after administration of naloxone were found in
the literature, both in multi-drug uses as in patients
receiving opiates for elective surgery.
Conclusion We suggest VT as a possible, but rarely
reported serious complication of naloxone administration
(Naranjo scale possible to probable). Patients who are
multi-drug users or receive opiates in high doses may be
prone to VT/VF due to acute (iatrogenic) opiate withdrawal
or reduction of sympathetic suppression and therefore
overstimulation. Also, antagonism of the protective
mechanism of opioids against sympathetic excess (due to
substance abuse, cardiac disease or hypoxia, as seen in all
cases) may induce VT/VF. We suggest the use of small
dosages (0.1 mg vs 0.4 mg), cardiac monitoring, and to
have defibrillation devices stand-by.
Key Points
Ventricular tachycardia is suggested to be a possible
but rarely reported complication of naloxone
administration.
Multi-drug users or patients receiving iatrogenic
high opiate doses may be prone to naloxone induced
ventricular tachycardia.
We suggest the use of small dosages, cardiac
monitoring, and to have defibrillation devices stand-
by when using naloxone in selected patients.
Introduction
Administration of naloxone, an opioid receptor antagonist
frequently used in overdose with morphine (iatrogenic) or
heroin, may not be as safe as previously considered.
Known adverse events of naloxone administration are
nausea, dizziness, headache and, in frequent opiate users,
acute (iatrogenic) opiate withdrawal syndrome. We
describe a patient who develops a ventricular tachycardia
(VT) after administration of naloxone. Furthermore, we
review the literature concerning VT following the use of
naloxone.
Written informed consent was obtained from the patient for
publication of this case report. A copy of the written consent is
available for review by the Editor-in-Chief of this journal.
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Case Report
A 44 year old former intravenous drug addict was brought
by ambulance to our emergency department with a reduced
state of consciousness. His medical history reveals hay
fever, chronic hepatitis C infection (hepatitis B and HIV
negative) and arthritis of his right knee. Furthermore, an
atrial septal defect had been discovered two years ago and
was surgically corrected. Being a former drugs addict, he
uses methadone 70 mg once a day, diazepam 10 mg three
times a day and promethazine 25 mg once a day if needed.
He uses no cardiovascular medication. Because of his
reduced mental state and his medical history a methadone
overdose or relapse in intravenous drug use, hence opioid
overdose, was suspected and naloxone (twice 0.4 mg intra-
osseous) was given following protocol by ambulance per-
sonnel before presentation at our emergency ward.
On arrival our patient was agitated but able to speak. His
airway was clear. His breathing was compromised with a
frequency of 40 breaths per minute (normal 14–20 per
minute) and normal breath sounds. Because of agitation
measuring saturation in this patient was difficult and there-
fore unreliable. Blood gas analysis showed a respiratory
alkalosis with normal oxygen pressures (pH 7.51
(7.35–7.45); pCO2 2.5 kPa (4.6–6.0); pO2 11.9 kPa
(9.5–13.5) HCO3 15 mmol/l (21–25)), oxygen saturation
98 % without oxygen administration. Because of tachypnea
he received a non-rebreathing mask with 15 l O2/min. He
showed a blood pressure of 140/78 mmHg, a tachycardia of
160–180 beats per minute (normal 60–100 bpm) and a
delayed capillary refill of 5 s (normal B 2 s). No murmurs
were heard at cardiac auscultation. Electrocardiography
shows frequent episodes of VT. His Glascow coma score is
reduced (4–4–2, normal 4–6–5), both pupils were dilated.
His temperature was 37 degrees Celsius, but rose to 39.6
degrees Celsius at secondary assessment half an hour later.
Additional laboratory results showed Calcium level of
1.86 mmol/l (2.20–2.60), Albumine 35 g/l (35–50), Potas-
sium 4.7 mmol/l (3.5–5.0) and Magnesium 0.97
(0.700–1.00). We concluded our patient to be in distributive
or cardiac shock. He received 2,250 mg Magnesiumsulphate
for his VT. Amiodarone 300 mg was given because of sus-
tained VT, without sufficient effect. Because of progressive
agitation despite administration of midazolam 5 mg,
increased frequency of breathing and difficulty in measuring
oxygen pressures because of agitation, he was sedated, using
propofol and roccuronium, and intubated. Additionally, an
arterial tube was placed in the brachial artery for frequent
blood gas analysis. A sudden fall in blood pressure made us
decide to perform electro cardioversion for VT (200 J),
which restored sinus rhythm. Our patient was subsequently
stabilized and admitted to our intensive care unit (ICU).
Myocardial infarction was ruled out by serial
electrocardiograms and the pattern of serial cardiac
enzymes. We contributed the initial rise in temperature to
rhabdomyolysis due to agitation, which developed further
during hospital stay (maximal CK-levels 91,716 U/l, normal
0–200 U/l; Myoglobin in urine 575 ug/l, normal 0–21 ug/l).
Rhabdomyolysis was treated with intravenous fluid admin-
istration and forced diuresis. Because of mixed sympat-
homimetic and opioid toxidrome at presentation in our ward,
multiple toxicology tests were performed once our patient
was stabilized. These showed signs of both amphetamines,
cannabis, benzodiazepine, opiate, methadone and cocaine.
Literature Review
Methods
We searched the MedLine database for Naloxone OR Narcan
AND ventricular tachycardia, Naloxone OR Narcan AND
‘‘Tachycardia, Ventricular’’[Mesh], Naloxone OR Narcan
AND ventricular fibrillation, Naloxone OR Narcan AND
‘‘Ventricular Fibrillation’’[Mesh], Naloxone OR Narcan
AND sudden cardiac death, Naloxone OR Narcan AND
‘‘Death, Sudden, Cardiac’’[Mesh]. Date last searched was
13-02-2014. Articles were excluded based on abstract and
title; studies describing only supraventricular arrhythmias,
stress cardiomyopathy without cardiac arrhythmias, animal
or in vitro studies were excluded. Articles not online avail-
able or directly available for the University Medical Centre
Groningen were bought. Duplicates were removed. Articles
considered significant were included by cross referencing. In
addition, we searched the Dutch and European public phar-
macovigilance databases (LAREB and Eudravigilance) for
VT as a side effect of naloxone administration.
Results
Only 7 studies describing 8 cases were found matching our
criteria, dating from 1974 to 2005. The Dutch and Euro-
pean public pharmacovigilance databases have not reported
VT as a side effect of naloxone administration. One report
described VT in a patient using Nalorphine. For compari-
son, see Table 1. The patient described by Cuss et al.
suffered VT shortly after administration of Naloxone [2]. A
second gift resulted in a second VT. Later, when read-
mitted, he again suffered VT twice, after 30 and 50 min.
Two patients died, one due to VT, one due to asystole.
Discussion
We reviewed the current literature concerning VT/VF
following the use of naloxone and contribute to this
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literature presenting our own case. The fact that we only
found 8 cases matching our search criteria indicated rarity
or underreporting. Of these, 6 described VT or ventricular
fibrillation (VF) following naloxone administration. Three
out of six patients suffering VT/VF were reported to be
frequent drug users (50 %), as was our patient. The use of
an opiate antagonist in frequent drug use may increase the
chance of acute opiate withdrawal syndrome, complicated
by VT/VF. Another two patients received high dose mor-
phine for cardiac surgery, which may as well trigger acute
opiate withdrawal syndrome when opiate antagonists are
used.
Our patient could have been more prone to arrhythmo-
genic events due to (late discovery and correction of) his
congenital heart disease and therefore structural cardiac
changes. Only two patients had a history with cardiac
disease, therefore susceptibility of the myocardium for
arrhythmogenic events could not be a sufficient explana-
tion for VT/VF in these patients.
Cocaine, as used by our patient, is known for its
arrhythmogenic and ischemic complications, and could
have contributed to the VT in our patient [8]. Cocaine was
used by only two of the other patients who suffered from
VT/VF; multi drug use was seen in both patients. Cocaine
alone, multi-drug use or an interaction with naloxone, can
therefore not be solely responsible for VT/VF in all of
these patients, and contribution of naloxone to the VF/VF
could be suspected.
At presentation our patient showed signs of insufficient
respiration. It had previously been suggested that VT fol-
lowing the use of naloxone could have been triggered by
hypoxia alone and not by administration of naloxone itself
[1, 4, 9]. However, only 2 out of 6 patients with VT/VF had
signs of insufficient ventilation in this review. Notably, in
all cases including our case VT/VF starts shortly after
administration of naloxone. However, short duration of this
interval suggests an association in these, cases, not per se
causality. The repeatability of VT in the case of Cuss et al.
[7] suggests an association as well, but could also be
attributed to ventricular irritability due to other mecha-
nisms in this patient despite lack of cardiac history.
Naloxone is suggested to increase or overstimulate
sympathetic activity by suddenly reducing the sympathetic
suppression of the administered opiate and therefore
increase the risk on VT/VF [2, 7]. Laboratory assessments
in dogs on morphine show only increased rate of ventric-
ular extra systoles after naloxone administration, but not
clearly increased ventricular irritability [6]. In all cases
sympathetic excess may have been caused by different
mechanisms, such as hypoxia, substance abuse or cardiac
disease. This combined with a sudden loss of the opioid
induced protection against arrhythmias due to naloxone
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in these patients. In addition, minor corrected QT interval
prolongation due to relatively high dose naloxone infusion
(40 ug/kg/min), and therefore possible susceptibility for
cardiac arrhythmias, has been described in a very small
population [10].
Worldwide accepted protocol administration of nalox-
one directs dosing of 0.4 mg, which may be repeated for
insufficient response. Smaller dosages have been used in
controlled settings (during anesthesiology) with sufficient
response. Starting with a dose of 0.1 mg and increasing the
dose slowly if needed may be the solution to prevent iat-
rogenic acute opiate withdrawal and therefore VT/VF in
these patients [11]. Another solution could be to abandon
administration of naloxone in opiate addicts, therefore
acute withdrawal syndrome cannot take place, and have
them intubated until awoken. However, this implicates
higher healthcare costs due to hospital and ICU stays and
should only be considered in patients at high risk for acute
opiate withdrawal syndrome (as multi-drug users or
patients who receive opiates in high doses). In other
patients the lifesaving potential of naloxone overweighs the
assumed risks, however, physicians need to be aware of
them.
Conclusion
We suggest that VT/VF may possibly (Naranjo scale, even
probable if previous reports are taken into account) be a
serious complication of naloxone administration [12].
Patients who are multi-drug users or receive opiates in high
doses may be prone to VT/VF due to acute (iatrogenic)
opiate withdrawal or reduction of sympathetic suppression
and therefore overstimulation. Also, antagonism of the
protective mechanism of opioids against sympathetic
excess (due to substance abuse, cardiac disease or hypoxia)
may induce VT/VF. We propose to be careful with nal-
oxone administration in these patients, and possibly choose
not to use naloxone at all in this selected group of patients.
If you do decide to administer naloxone, consider using
small dosages (0.1 mg vs 0.4 mg) and have defibrillation
devices stand-by. More research would help to determine
the frequency and exactness of this possible complication,
because, while highly interesting, current literature is
scarce, evidence is little and our assumptions are made
based on small proportions. However, ethical objections
may preclude administration of naloxone in healthy indi-
viduals to prove causality for VT/VF as a complication of
this opiate antagonist. Awareness and thereby more fre-
quent reporting of this adverse event might also be
important.
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